Aardvark Therapeutics (AARD) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Aardvark Therapeutics (NASDAQ: AARD) in the last few weeks:

• 5/15/2026 – Aardvark Therapeutics had its price target lowered by B. Riley Financial, Inc. from $8.00 to $7.00. They now have a “buy” rating on the stock.
• 5/15/2026 – Aardvark Therapeutics was downgraded by BTIG Research from “buy” to “hold”.
• 5/15/2026 – Aardvark Therapeutics had its “underweight” rating reaffirmed by Morgan Stanley. They now have a $3.00 price target on the stock, down from $7.00.
• 5/13/2026 – Aardvark Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 4/29/2026 – Aardvark Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.